reviewDiabetes CareJun 6, 2024BRONZE OA

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity

DJDaniel J. Drucker

Mount Sinai Hospital · University of Toronto · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1-based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate…

Citation impact

301
total citations
FWCI
94.00
Percentile
100%
References
172
Citations per year

Authors

1

Topics & keywords

Topics
Keywords
  • Medicine
  • Type 2 diabetes
  • Diabetes mellitus
  • Exenatide
  • Disease
  • Glucagon-like peptide-1
  • Obesity
  • Bioinformatics
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding